Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introduction We conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America. Methods A total of 537 Japanese subjects with normal cognition, late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD) were enrolled using the same criteria as ADNI. Rates of changes in representative cognitive or functional measures were compared for amyloid positron emission tomography- or cerebrospinal fluid amyloid β(1-42)-positive LMCI and mild AD between J-ADNI and ADNI. Results Amyloid positivity rates were significantly higher in normal cognition of ADNI but at similar levels in LMCI and mild AD between J-ADNI and ADNI. Profiles of decline in cognitive or functional measures in amyloid-positive LMCI in J-ADNI (n = 75) and ADNI (n = 269) were remarkably similar, whereas those in mild AD were milder in J-ADNI (n = 73) compared with ADNI (n = 230). Discussion These results support the feasibility of bridging of clinical trials in the prodromal stage of AD between Asia and western countries.

What this study adds

Evidence grade: Low

The record lists 75 participants. Amyloid positivity was similar between regions in MCI and mild AD but higher among cognitively normal ADNI participants. The authors say this supports the "feasibility" of running early-stage (prodromal) Alzheimer's trials across Asia and Western countries; the study tested no treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Iwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., et al. (2018). Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2018.03.009

Vancouver

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2018. doi:10.1016/j.jalz.2018.03.009. PMID: 29753531.

BibTeX

@article{iwatsubo2018-29753531,
  author  = {Iwatsubo, T. and Iwata, A. and Suzuki, K. and Ihara, R. and Arai, H. and Ishii, K. and Senda, M. and Ito, K. and others},
  title   = {{Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2018},
  doi     = {10.1016/j.jalz.2018.03.009},
  pmid    = {29753531},
  url     = {https://doi.org/10.1016/j.jalz.2018.03.009}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Using the same enrolment criteria as North America's ADNI, the Japanese J-ADNI study found that people with amyloid-positive late amnestic mild cognitive impairment declined in "remarkably similar" ways in both regions (75 Japanese vs 269 North American participants), while decline in mild Alzheimer's disease was milder in the Japanese group (73 vs 230). Amyloid positivity was similar between regions in MCI and mild AD but higher among cognitively normal ADNI participants. The authors say this supports the "feasibility" of running early-stage (prodromal) Alzheimer's trials across Asia and Western countries; the study tested no treatment.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 52 of the 96 points it could be judged on, which is 54 of 100. Total 54 of 100.52 of the 96 points we could judge = 54 of 100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 52 of the 96 points we could judge it on, which is 54 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 1 / 4 75 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 142 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.2 citations a year over 10 year(s) since 2018
Impact for its field and year 4 / 6 Cited 9.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 3 / 4 Cited 53 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29753531)
Free to read 0 / 2 Behind a paywall — scores zero
Points 52 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 52 of the 96 points we could judge it on is 54 out of 100.
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Mild cognitive impairment from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →